|
gptkbp:instanceOf
|
antiviral drug
nucleotide analogue
|
|
gptkbp:approvedBy
|
gptkb:FDA
1996
|
|
gptkbp:ATCCode
|
J05AB12
|
|
gptkbp:brand
|
gptkb:Vistide
|
|
gptkbp:CASNumber
|
113852-37-2
|
|
gptkbp:category
|
antiviral
orphan drug
nucleoside phosphonate
|
|
gptkbp:contraindication
|
renal impairment
|
|
gptkbp:discoveredBy
|
gptkb:Gilead_Sciences
|
|
gptkbp:eliminationHalfLife
|
2.6 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:hasMolecularFormula
|
C8H14N3O6P
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
cidofovir
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits viral DNA polymerase
|
|
gptkbp:metabolism
|
not significantly metabolized
|
|
gptkbp:molecularWeight
|
279.19 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1423
60607
DB00523
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
proteinuria
nephrotoxicity
neutropenia
|
|
gptkbp:UNII
|
8T49QOQ44I
|
|
gptkbp:usedFor
|
treatment of adenovirus infections
treatment of cytomegalovirus retinitis
treatment of poxvirus infections
|
|
gptkbp:bfsParent
|
gptkb:Vaccinia_virus
gptkb:Cytomegalovirus
gptkb:cytomegalovirus_infection
gptkb:Human_herpesvirus_8
gptkb:cytomegalovirus
|
|
gptkbp:bfsLayer
|
6
|